A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab

Detalles Bibliográficos
Autores principales: Fischer, Stefanie, Götze, Thorsten O., Omlin, Aurelius, Baird, Richard D., Dawson, Keith M., Zitt, Christof, Arany, Zita, Tresch, Gaby, Fiedler, Ulrike, Jeger, Simone, Fung, Samson, Legenne, Philippe, Leupin, Nicolas, Schneeweiss, Andreas, Fremd, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666114/
https://www.ncbi.nlm.nih.gov/pubmed/36331248
http://dx.doi.org/10.1200/PO.22.00006
_version_ 1784831430786809856
author Fischer, Stefanie
Götze, Thorsten O.
Omlin, Aurelius
Baird, Richard D.
Dawson, Keith M.
Zitt, Christof
Arany, Zita
Tresch, Gaby
Fiedler, Ulrike
Jeger, Simone
Fung, Samson
Legenne, Philippe
Leupin, Nicolas
Schneeweiss, Andreas
Fremd, Carlo
author_facet Fischer, Stefanie
Götze, Thorsten O.
Omlin, Aurelius
Baird, Richard D.
Dawson, Keith M.
Zitt, Christof
Arany, Zita
Tresch, Gaby
Fiedler, Ulrike
Jeger, Simone
Fung, Samson
Legenne, Philippe
Leupin, Nicolas
Schneeweiss, Andreas
Fremd, Carlo
author_sort Fischer, Stefanie
collection PubMed
description
format Online
Article
Text
id pubmed-9666114
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-96661142022-11-16 A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab Fischer, Stefanie Götze, Thorsten O. Omlin, Aurelius Baird, Richard D. Dawson, Keith M. Zitt, Christof Arany, Zita Tresch, Gaby Fiedler, Ulrike Jeger, Simone Fung, Samson Legenne, Philippe Leupin, Nicolas Schneeweiss, Andreas Fremd, Carlo JCO Precis Oncol Case Reports Wolters Kluwer Health 2022-11-03 /pmc/articles/PMC9666114/ /pubmed/36331248 http://dx.doi.org/10.1200/PO.22.00006 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Case Reports
Fischer, Stefanie
Götze, Thorsten O.
Omlin, Aurelius
Baird, Richard D.
Dawson, Keith M.
Zitt, Christof
Arany, Zita
Tresch, Gaby
Fiedler, Ulrike
Jeger, Simone
Fung, Samson
Legenne, Philippe
Leupin, Nicolas
Schneeweiss, Andreas
Fremd, Carlo
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
title A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
title_full A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
title_fullStr A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
title_full_unstemmed A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
title_short A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab
title_sort case of sustained tumor regression with mp0274, a novel darpin therapeutic targeting human epidermal growth factor receptor 2 signaling, in metastatic human epidermal growth factor receptor 2–positive breast cancer after prior trastuzumab and pertuzumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666114/
https://www.ncbi.nlm.nih.gov/pubmed/36331248
http://dx.doi.org/10.1200/PO.22.00006
work_keys_str_mv AT fischerstefanie acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT gotzethorsteno acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT omlinaurelius acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT bairdrichardd acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT dawsonkeithm acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT zittchristof acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT aranyzita acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT treschgaby acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT fiedlerulrike acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT jegersimone acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT fungsamson acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT legennephilippe acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT leupinnicolas acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT schneeweissandreas acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT fremdcarlo acaseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT fischerstefanie caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT gotzethorsteno caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT omlinaurelius caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT bairdrichardd caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT dawsonkeithm caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT zittchristof caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT aranyzita caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT treschgaby caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT fiedlerulrike caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT jegersimone caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT fungsamson caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT legennephilippe caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT leupinnicolas caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT schneeweissandreas caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab
AT fremdcarlo caseofsustainedtumorregressionwithmp0274anoveldarpintherapeutictargetinghumanepidermalgrowthfactorreceptor2signalinginmetastatichumanepidermalgrowthfactorreceptor2positivebreastcancerafterpriortrastuzumabandpertuzumab

Ejemplares similares